GB2397018A - Combination therapy for treating disease - Google Patents

Combination therapy for treating disease Download PDF

Info

Publication number
GB2397018A
GB2397018A GB0409191A GB0409191A GB2397018A GB 2397018 A GB2397018 A GB 2397018A GB 0409191 A GB0409191 A GB 0409191A GB 0409191 A GB0409191 A GB 0409191A GB 2397018 A GB2397018 A GB 2397018A
Authority
GB
United Kingdom
Prior art keywords
antigen
immune response
binding agent
host immune
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB0409191A
Other versions
GB0409191D0 (en
GB2397018B (en
Inventor
Birgit C Schultes
Christopher F Nicodemus
Antoine Noujaim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altarex Medical Corp
Original Assignee
Altarex Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altarex Medical Corp filed Critical Altarex Medical Corp
Publication of GB0409191D0 publication Critical patent/GB0409191D0/en
Publication of GB2397018A publication Critical patent/GB2397018A/en
Application granted granted Critical
Publication of GB2397018B publication Critical patent/GB2397018B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are methods for treating cancer comprising administering a xenotypic monoclonal antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen in present in the host serum, which antigen does not elicit a host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein a host immune response is elicited against a second epitope on the antigen.

Description

GB 2397018 A continuation (74) Agent and/or Address for Service:
Cruikshank & Fairweather 19 Royal Exchange Square, GLASGOW, G1 3AE, United Kingdom
GB0409191A 2001-10-26 2002-10-28 Combination therapy for treating disease Expired - Fee Related GB2397018B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33924001P 2001-10-26 2001-10-26
PCT/IB2002/005794 WO2003034977A2 (en) 2001-10-26 2002-10-28 Combination therapy for treating disease

Publications (3)

Publication Number Publication Date
GB0409191D0 GB0409191D0 (en) 2004-05-26
GB2397018A true GB2397018A (en) 2004-07-14
GB2397018B GB2397018B (en) 2006-05-31

Family

ID=23328122

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0409191A Expired - Fee Related GB2397018B (en) 2001-10-26 2002-10-28 Combination therapy for treating disease

Country Status (9)

Country Link
AT (1) AT500649A1 (en)
AU (1) AU2002358246B2 (en)
CA (1) CA2464947C (en)
CH (1) CH696871A5 (en)
DE (1) DE10297379T5 (en)
ES (1) ES2304264A1 (en)
GB (1) GB2397018B (en)
NO (1) NO20042166L (en)
WO (1) WO2003034977A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
WO2008091643A2 (en) * 2007-01-23 2008-07-31 Altarex Medical Corp. In vitro culture system to evaluate synergy in targeting immune suppressive pathways concurrent to immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163868C (en) * 1993-05-27 2008-01-08 Uwe Wagner Monoclonal anti-idiotypic anti-ca125 antibodies and pharmaceutical compositions containing them
ES2193240T3 (en) * 1996-05-15 2003-11-01 Altarex Inc METHOD AND COMPOSITION TO RECONFORM MULTI-EPITHOPIC ANTIGENS TO START AN IMMUNE RESPONSE.
IL146954A0 (en) * 1999-06-25 2002-08-14 Genentech Inc HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
JP2003505432A (en) * 1999-07-23 2003-02-12 グラクソ グループ リミテッド Combination of anti-EP-CAM antibody and chemotherapeutic agent
ATE290879T1 (en) * 1999-08-18 2005-04-15 Altarex Medical Corp THERAPEUTIC ANTIBODIES AGAINST THE MUC-1 ANTIGEN AND METHOD FOR USE THEREOF
PL202369B1 (en) * 1999-08-27 2009-06-30 Genentech Inc DOSAGES FOR TREATMENT WITH ANTI−ErbB2 ANTIBODIES
PT1254374E (en) * 2000-02-08 2007-07-20 Altarex Medical Corp Method for diagnosing efficacy of xenotypic antibody therapy
WO2002076384A2 (en) * 2001-03-21 2002-10-03 Altarex Corp. Therapeutic compositions that alter the immune response

Also Published As

Publication number Publication date
CA2464947A1 (en) 2003-05-01
AU2002358246B2 (en) 2008-02-28
CA2464947C (en) 2012-05-22
WO2003034977A3 (en) 2004-05-27
AT500649A1 (en) 2006-02-15
CH696871A5 (en) 2008-01-15
GB0409191D0 (en) 2004-05-26
WO2003034977A2 (en) 2003-05-01
DE10297379T5 (en) 2004-10-14
GB2397018B (en) 2006-05-31
ES2304264A1 (en) 2008-10-01
NO20042166L (en) 2004-05-25

Similar Documents

Publication Publication Date Title
IL126803A (en) Method and composition for reconforming multiepitopic antigens to initiate an immune response
RU2008128244A (en) METHODS FOR IDENTIFICATION OF TUMORS SUSCEPTIBLE TO TREATMENT BY ANTIBODIES AGAINST ERBB2
IL192679A0 (en) Aglyco products and uses thereof
HUP0200537A2 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
WO2000052054A3 (en) Antibodies for cancer therapy and diagnosis
HUP0303173A2 (en) Modified anti-egfr antibodies with reduced immunogenicity
WO2001005425A3 (en) Combined preparations comprising daunorubicin derivatives and her2 antibodies
EP2022800A3 (en) Compositions for the therapy and diagnosis of ovarian cancer
CA2249320A1 (en) Glycosylated humanized b-cell specific antibodies
AU563356B2 (en) Conjugate of enzyme and antibody
JP2003519096A5 (en)
CA2348026A1 (en) Antibodies against semp1, methods for their production and uses thereof
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
EP1354896A4 (en) Novel monoclonal antibody
WO2000069915A3 (en) COMBINED APPROACH TO TREATMENT OF CANCER WITH hCG VACCINES
CA2431199A1 (en) Immunotherapeutic kit for the treatment of tumors
GB2397018A (en) Combination therapy for treating disease
WO2004003155A3 (en) Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
WO2002100343A3 (en) N-terminally truncated galectin-3 and antibodies for treating cancer
AU2629892A (en) Monoclonal antibodies against tumor-associated antigens, processes for the preparation thereof and the use thereof
AU2070688A (en) Antigen recognized by mca 16-88
EP0537168A4 (en) Ctaa 28a32, the antigen recognized by mca 28a32
WO2001036485A3 (en) Recombinant monoclonal antibodies recognizing antigen ior c2 and the use thereof in the diagnosis and treatment of colorectal tumors
AU2002326318A1 (en) Targeting tumor cell antigens: antibodies useful for the diagnosis, prognosis, and treatment of cancer
WO2001075023A3 (en) A novel polypeptide, human phosphatidylinositol-3 (ptdins 3) kinase 9 and the polynucleotide encoding the polypeptide

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20151217 AND 20151223

732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20200618 AND 20200624

732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20201029 AND 20201104

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20211028